BLVRA抗体—艾普蒂

BLVRA (biliverdin reductase A) is a critical enzyme in the heme degradation pathway, responsible for reducing biliverdin to bilirubin, a potent antioxidant. This process plays a key role in cellular defense against oxidative stress. The BLVRA gene is widely expressed across tissues, including the liver, brain, and cardiovascular systems, with emerging links to diseases like neurodegeneration, diabetes, and cancer. BLVRA antibodies are immunological tools developed to detect and quantify BLVRA protein expression in research settings. They are typically produced using recombinant BLVRA proteins or synthetic peptides as immunogens. These antibodies enable studies of BLVRA's regulatory mechanisms, subcellular localization, and interactions with other redox-related molecules. Validated applications include Western blotting, immunohistochemistry, and ELISA. Recent research leverages BLVRA antibodies to explore its dual role in both antioxidant protection and paradoxical pro-oxidant effects under certain pathological conditions. Specificity is often confirmed through knockout cell line validation. The antibody's utility extends to investigating BLVRA's potential as a therapeutic target or biomarker in metabolic disorders, chronic inflammation, and age-related diseases. Commercial BLVRA antibodies are available from multiple suppliers, with cross-reactivity varying between species (human, mouse, rat).